NEUROSENSE THERAPEUTICS LTD (NRSN)       1.63  -0.02 (-1.21%)

1.63  -0.02 (-1.21%)

IL0011809592 - Common Stock - After market: 1.58 -0.05 (-3.07%)

NEUROSENSE THERAPEUTICS LTD1.63

NASDAQ:NRSN (2/3/2023, 7:00:03 PM)-0.02 (-1.21%)

After market: 1.58 -0.05 (-3.07%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology

Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend

Overview
Earnings (Last) 08-31 2022-08-31/bmo Earnings (Next) 12-13 2022-12-13/bmo
Ins Owners N/A Inst Owners N/A
Market Cap 19.03M Shares 11.67M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 82.86
IPO 12-09 2021-12-09

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

NRSN Daily chart

Company Profile

Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company. The firm is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The firm's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease

Company Info

NEUROSENSE THERAPEUTICS LTD

11 Hamenofim St., Building B

Herzliya

P: 97299531142.0

Employees: 11

Website: https://www.neurosense-tx.com/

NRSN News

News Image16 days ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

It's the final day of trading this week and we're checking in on the biggest pre-market stock movers for Friday morning!

News Image17 days ago - InvestorPlaceWhy Is NeuroSense (NRSN) Stock Up 98% Today?

NeuroSense (NRSN) stock is taking off on Thursday as investors react to data from a biomarker study concerning Alzheimer's disease (AD).

News Image17 days ago - Seeking AlphaNeuroSense Therapeutics surges 92% on Alzheimer's biomarker study results (NASDAQ:NRSN)

Microcap NeuroSense Therapeutics (NRSN) is up 92% in Thursday morning trading after the reporting positive results for a biomarker study of its combination platform therapy for Alzheimer's.

News Image17 days ago - NeurosenseNeuroSense Therapeutics Reports Positive Final Results from Alzheimer's Biomarker Study

/PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today...

News Image2 months ago - NeurosenseNeuroSense Announces Third Quarter 2022 Financial Results and Provides Business Update

/PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today...

News Image3 months ago - NeurosenseNeuroSense Receives Regulatory Approval to Commence Patient Enrollment in Italy for its Phase 2b Trial in ALS

/PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today...

NRSN Twits

Here you can normally see the latest stock twits on NRSN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example